The biopharmaceutical industry is increasingly turning to data-driven, in silico methods to overcome growing downstream processing challenges, enabling faster resin selection and more efficient development of complex biologics at scale.
This presentation addresses the critical need for high-throughput, reliable analytical development strategies to support expedited Investigational New Drug (IND) applications.
Oxygen heterogeneity in large-scale bioreactors — driven by pressure variations and other scale-dependent factors — can affect cell growth and yield, underscoring the need for precise control and process understanding to ensure successful manufacturing and tech transfer.
Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish for biologics. With commercialization in mind, we expand our development portfolio and continue to offer better service to fit clients' needs. Our facilities are cGMP compliant with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.
